Targeting BRCA2 deficiency with GSK3 inhibitors

Targeting BRCA2 deficiency with GSK3 inhibitors

<p>BRCA1 and BRCA2 tumour suppressors are essential for homologous recombination-mediated double-strand break repair and replication fork protection. Therefore, BRCA1 and BRCA2 are essential for cell viability. Deactivating mutations in one of these genes lead to genome instability and are ass...

Deskribapen osoa

Xehetasun bibliografikoak
Egile nagusia:	Zonderland, G
Beste egile batzuk:	Tarsounas, M
Formatua:	Thesis
Argitaratua:	2017

Antzeko izenburuak

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
nork: Tacconi, E, et al.
Argitaratua: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
nork: Eliana MC Tacconi, et al.
Argitaratua: (2019-05-01)

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds
nork: Zimmer, J, et al.
Argitaratua: (2016)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
nork: Ashwin Ragupathi, et al.
Argitaratua: (2023-03-01)

Novel approaches for targeting BRCA2-deficient tumour cells
nork: Tacconi, E
Argitaratua: (2015)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
nork: Ilirjana Bajrami, et al.
Argitaratua: (2021-11-01)

GSK-3 inhibitors induce chromosome instability
nork: Staples Oliver D, et al.
Argitaratua: (2007-08-01)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
nork: Rebecca A. Dagg, et al.
Argitaratua: (2021-08-01)

Lithium and Therapeutic Targeting of GSK-3
nork: Melinda E. Snitow, et al.
Argitaratua: (2021-01-01)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
nork: Giuseppa Augello, et al.
Argitaratua: (2020-06-01)

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
nork: Xuexia Xie, et al.
Argitaratua: (2024-10-01)

Machine Learning for Discovery of GSK3β Inhibitors
nork: Patricia A. Vignaux, et al.
Argitaratua: (2020-10-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
nork: Hagit eEldar-Finkelman, et al.
Argitaratua: (2011-10-01)

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
nork: Sorin Hostiuc, et al.
Argitaratua: (2019-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
nork: Shicheng Yang, et al.
Argitaratua: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
nork: Tingting Du, et al.
Argitaratua: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
nork: Karolina N. Dziadkowiec, et al.
Argitaratua: (2017-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
nork: Tacconi, E, et al.
Argitaratua: (2017)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
nork: Qianye Yang, et al.
Argitaratua: (2021-04-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
nork: Zatreanu, D, et al.
Argitaratua: (2021)

Targeting of CRMP-2 to the primary cilium is modulated by GSK-3β.
nork: Young Ou, et al.
Argitaratua: (2012-01-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
nork: Eliana MC Tacconi, et al.
Argitaratua: (2017-07-01)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
nork: Julieta Martino, et al.
Argitaratua: (2023-04-01)

The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
nork: Ata ur Rahman Mohammed Abdul, et al.
Argitaratua: (2018-01-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
nork: Diana Zatreanu, et al.
Argitaratua: (2021-06-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
nork: Yosuke Akiba, et al.
Argitaratua: (2016-03-01)

Novel reporter alleles of GSK-3α and GSK-3β.
nork: William B Barrell, et al.
Argitaratua: (2012-01-01)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
nork: Julieta Martino, et al.
Argitaratua: (2023-11-01)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
nork: Przemysław Duda, et al.
Argitaratua: (2020-04-01)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
nork: Salar Farokhi Boroujeni, et al.
Argitaratua: (2023-11-01)

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.
nork: Sin-Aye Park, et al.
Argitaratua: (2016-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
nork: Robert A. Smith, et al.
Argitaratua: (2023-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
nork: Robert A Smith, et al.
Argitaratua: (2023-01-01)

Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
nork: Martinez, Ana, 1961-, et al.
Argitaratua: (2006)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
nork: Xia Ding, et al.
Argitaratua: (2016-08-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
nork: Geoffrey I Shapiro, et al.
Argitaratua: (2023-11-01)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
nork: Melissa S Cline, et al.
Argitaratua: (2018-12-01)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
nork: Suggala Ramya Shri, et al.
Argitaratua: (2023-11-01)

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
nork: Rosa Buonfiglio, et al.
Argitaratua: (2020-05-01)

Computational study of some cancer drugs as potent inhibitors of GSK3β
nork: David Ebuka Arthur, et al.
Argitaratua: (2020-11-01)